Ser1029

Site Information
QMNHALFsLNGRtGy SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 23132731

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 )
Disease tissue studied:	brain cancer ( 3 ) , glioblastoma ( 3 ) , glioma ( 3 ) , gastric cancer ( 1 ) , gastric carcinoma ( 1 )
Relevant cell line - cell type - tissue:	Jurkat (T lymphocyte) ( 2 ) , M059K (glial) ( 3 ) , MKN-45 (gastric) ( 1 )

References
1	Moritz A (2010) CST Curation Set: 10232; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Curated Info
2	Possemato A (2007) CST Curation Set: 3170; Year: 2007; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
3	Stokes M (2007) CST Curation Set: 2262; Year: 2007; Biosample/Treatment: cell line, M059K/UV; Disease: glioblastoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) ATM/ATR Substrate Antibody Cat#: 2851 Curated Info